Latest News and Press Releases

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented yesterday at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards, Inc., (NASDAQ: MSHL) today announced that it will be undertaking an un-blinded analysis of the data from its...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William D. Rueckert to its Board of...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the Board of Directors of the...

NEW CANAAN, CT--(Marketwire - March 18, 2009) - NV-128, a Novogen, Ltd. (ASX: NRT) (NASDAQ: NVGN) compound, induced cell death in ovarian cancer stem cells in a dose-dependent manner. The study...

NEW CANAAN, CT--(Marketwire - March 18, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL). An abstract titled "Pre-clinical Toxicology of Triphendiol (NV-196)" will be presented at the Annual Meeting of...

ORLANDO, FL--(Marketwire - February 24, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) -- Preliminary results from a Phase II clinical trial of oral phenoxodiol in patients with prostate cancer to be...

SYDNEY, AUSTRALIA--(Marketwire - February 13, 2009) - Australian pharmaceutical R&D company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) today advised it would focus its activities on its oncology...

WASHINGTON, DC--(Marketwire - January 14, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) will present at the 27th Annual JPMorgan Healthcare Conference in San Francisco on Thursday January 15, 2008 at...

NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has been granted an Investigative New Drug (IND) approval by the United States Food and...